The FDA has accepted an investigational new drug application for Nicox’s topical blepharitis treatment, the company announced in a press release.
NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, is being developed as a targeted treatment of the eyelid margin for patients with acute exacerbations of blepharitis, the release said.
The company plans to announce a first-in-human, randomized, placebo-controlled, phase 2 clinical trial in the second half of this year.
Uncategorized